|
|
Other links at Articles > Cardiology |
| 2. |
First Data on Aliskiren in Diabetic Nephropathy
|
|
|
The first trial of the new direct renin inhibitor, aliskiren, in patients with diabetic nephropathy shows that it reduces proteinuria when added to conventional treatment. But observers say this is merely a surrogate-end-point trial and definitive guidance on how to use this drug in such patients will come only from an ongoing large outcomes study, ALTITUDE. Heartwire
|
| 3. |
Spotlight on HDL-raising Therapies: Insights From the Torcetrapib Trials
|
|
|
A large trial of a medication designed to raise HDL was stopped early because of a higher risk for death among subjects receiving active treatment. However, HDL-raising therapy may still have an important role in the prevention or management of cardiovascular disease. The current article reviews these treatments. Nature Clinical Practice Cardiovascular Medicine
|
|
|
